Explore

Trendline Trendline
Kivu Bioscience to Present Preclinical Data on Next-Generation ADC Programs at AACR Annual Meeting

Kivu Bioscience to Present Preclinical Data on Next-Generation ADC Programs at AACR Annual Meeting

Kivu Bioscience to Present Preclinical Data on Next-Generation ADC Programs at AACR Annual Meeting
Trendline Trendline
Kivu Bioscience to Showcase ADC Innovations at AACR Annual Meeting 2026

Kivu Bioscience to Showcase ADC Innovations at AACR Annual Meeting 2026

Kivu Bioscience to Showcase ADC Innovations at AACR Annual Meeting 2026
Trendline Trendline
San Diego Startup Neomorph Secures $100 Million Investment for Cancer Drug Development

San Diego Startup Neomorph Secures $100 Million Investment for Cancer Drug Development

San Diego Startup Neomorph Secures $100 Million Investment for Cancer Drug Development
Trendline Trendline
San Diego Startup Neomorph Secures $100M for Cancer Drug Development

San Diego Startup Neomorph Secures $100M for Cancer Drug Development

San Diego Startup Neomorph Secures $100M for Cancer Drug Development
Trendline Trendline
Parabilis Medicines Appoints New Executives to Drive Growth and Innovation

Parabilis Medicines Appoints New Executives to Drive Growth and Innovation

Parabilis Medicines Appoints New Executives to Drive Growth and Innovation
Trendline Trendline
IDEAYA and Servier's PKC Drug Shows Promise in Uveal Melanoma Trial

IDEAYA and Servier's PKC Drug Shows Promise in Uveal Melanoma Trial

IDEAYA and Servier's PKC Drug Shows Promise in Uveal Melanoma Trial
Trendline Trendline
Iterion Therapeutics Presents New Data on Tegavivint for Wnt-Driven Cancers at AACR Meeting

Iterion Therapeutics Presents New Data on Tegavivint for Wnt-Driven Cancers at AACR Meeting

Iterion Therapeutics Presents New Data on Tegavivint for Wnt-Driven Cancers at AACR Meeting
Trendline Trendline
Parabilis Medicines Strengthens Leadership with Key Appointments to Drive Growth

Parabilis Medicines Strengthens Leadership with Key Appointments to Drive Growth

Parabilis Medicines Strengthens Leadership with Key Appointments to Drive Growth
Trendline Trendline
Natera Reports Positive Interim Analysis from Allogene's ALPHA3 Trial in Large B-Cell Lymphoma

Natera Reports Positive Interim Analysis from Allogene's ALPHA3 Trial in Large B-Cell Lymphoma

Natera Reports Positive Interim Analysis from Allogene's ALPHA3 Trial in Large B-Cell Lymphoma
Trendline Trendline
BioNTech and DualityBio Report Promising Results in Mid-Stage Endometrial Cancer Trial

BioNTech and DualityBio Report Promising Results in Mid-Stage Endometrial Cancer Trial

BioNTech and DualityBio Report Promising Results in Mid-Stage Endometrial Cancer Trial
Trendline Trendline
IDEAYA Biosciences to Reveal Phase 2/3 Trial Results for Metastatic Uveal Melanoma

IDEAYA Biosciences to Reveal Phase 2/3 Trial Results for Metastatic Uveal Melanoma

IDEAYA Biosciences to Reveal Phase 2/3 Trial Results for Metastatic Uveal Melanoma
Trendline Trendline
IDEAYA and Servier's Eye Cancer Drug Advances to FDA with Promising Efficacy

IDEAYA and Servier's Eye Cancer Drug Advances to FDA with Promising Efficacy

IDEAYA and Servier's Eye Cancer Drug Advances to FDA with Promising Efficacy